Welcome to our dedicated page for Akebia Therapeutics SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Akebia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Akebia Therapeutics's regulatory disclosures and financial reporting.
Akebia Therapeutics, Inc. SVP, CFO, CBO & Treasurer Erik Ostrowski reported an open-market sale of 56,019 shares of common stock at $1.11 per share on June 29, 2026. According to the footnote, this was an automatic “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units granted on June 28, 2024, executed under durable instructions adopted on September 8, 2025. After the sale, he directly holds 616,616 shares of Akebia common stock.
Akebia Therapeutics reported interim results from the VOICE trial of Vafseo in dialysis patients with anemia due to chronic kidney disease. The randomized, active-controlled safety study in 2,116 patients met predefined stopping criteria, showing Vafseo was both non-inferior and superior to an erythropoiesis-stimulating agent on the primary composite endpoint of all-cause mortality and hospitalization.
The interim analysis as of June 1, 2026 showed a win odds of 1.16 (95% CI 1.06, 1.28, p=0.0016). Hospitalizations were lower with Vafseo at 1.11 versus 1.23 per patient-year, with an incidence rate ratio of 0.90 (95% CI 0.824, 0.988), while mortality rates were similar between groups at 8.77% versus 8.78% per 100 patient-years.
Akebia Therapeutics submitted a Form 144 notice related to Common Stock tied to the vesting of restricted stock units on 06/28/2026. The filing lists 56,019 in connection with the equity compensation event and references Nasdaq and the date 06/29/2026.
Akebia Therapeutics director Myles Wolf received equity awards as part of non-employee director compensation. He was granted 35,700 shares of Common Stock in the form of restricted stock units and a stock option for 53,600 shares at an exercise price of $1.02 per share. Both the RSUs and the option vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant, if that occurs sooner, subject to his continued service. Following the award, he directly owns 169,081 Common Shares and holds the newly granted option for 53,600 underlying shares.
Akebia Therapeutics director Cynthia Smith received new equity awards as part of non-employee director compensation. She was granted 35,700 restricted stock units and an option for 53,600 shares of common stock at an exercise price of $1.02 per share. Both awards vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving. After the RSU grant, she directly holds 196,633 common shares.
Akebia Therapeutics, Inc. reported that director Michael W. Rogers received new equity awards. He acquired 35,700 shares of common stock in the form of restricted stock units granted at no cash cost and not yet vested. He also received a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share. Both the RSUs and the option vest in full on the first anniversary of the June 17, 2026 grant date, or immediately before the first annual stockholder meeting after that date, if earlier, subject to his continuous service. Following these awards, he directly holds 197,429 shares of common stock and 53,600 stock options.
Akebia Therapeutics director Ron Frieson received equity awards as part of his director compensation. He was granted 35,700 restricted stock units under the 2023 Stock Incentive Plan, increasing his direct common stock holdings to 165,200 shares. He was also granted stock options for 53,600 shares at an exercise price of $1.02 per share.
Both the RSUs and the stock options vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholders’ meeting after that date, if he continues serving the company through vesting.
Akebia Therapeutics’ stockholders held their 2026 annual meeting and approved several corporate matters. They elected three Class III directors – Adrian Adams, Michael Rogers and LeAnne M. Zumwalt – to serve until the 2029 annual meeting. Stockholders also approved a Share Increase Amendment to the certificate of incorporation, raising authorized capital stock from 375,000,000 to 525,000,000 shares and authorized common stock from 350,000,000 to 500,000,000 shares, with 102,504,108 votes for and 88,853,129 against. In advisory votes, stockholders approved named executive officer compensation and recommended that say-on-pay votes occur every year. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Akebia Therapeutics director Leanne M. Zumwalt received equity awards in the form of common stock and stock options. She was granted 35,700 shares of Common Stock as restricted stock units under Akebia’s 2023 Stock Incentive Plan, bringing her direct common stock holdings to 145,100 shares after the grant.
She was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the RSUs and the option vest 100% on the first anniversary of the grant date, or earlier immediately before the first annual meeting of stockholders after the grant, if she continues serving the company.
Akebia Therapeutics, Inc. director Adrian Adams reported awards of equity-based compensation. He received 35,700 shares of common stock as restricted stock units that were granted at no cash price and increase his direct holdings to 236,200 common shares after the award.
Adams was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the restricted stock units and the stock option are scheduled to vest in full on the first anniversary of the grant date, or earlier immediately before the first annual stockholder meeting after the grant, subject to his continuous service to the company.